ABOUT THE COMPANY. Bharat Petroleum Corporation Ltd. (BPCL) is a Fortune 500 Maharatna Oil Refining and Marketing company in India. The company produces a diverse range of products, from petrochemicals and solvents to aircraft fuel and specialty lubricants and markets them through its wide network of Petrol Stations, Kerosene Dealers, LPG Distributors and Lube Shoppe’s. The HRS Entity is engaged in the creation, maintenance and upkeep of Offices and Residential Complexes for Staff located across the country.
ABOUT THE COMPANY. Far Resources Ltd. is an exploration company, publicly traded on the Canadian Securities Exchange under the symbol FAT, focused on the identification and development of high potential mineral opportunities in stable jurisdictions. ON BEHALF OF THE BOARD OF DIRECTORS OF FAR RESOURCES LTD.
ABOUT THE COMPANY. The Company is a leading biopharmaceutical company in China with a fully integrated proprietary biologics platform in bispecific and protein engineering. The Company’s highly differentiated in-house pipeline consists of monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates in staggered development status in oncology, including, among others, one approved for marketing by the National Medical Products Administration of China (國家藥品監督管理局) and three in late clinical stage. The Company has developed various technologies and platforms of antibody-based therapies for oncology treatment and expertise in this regard. Benefitting from the proprietary protein engineering platforms and structure-guided molecular modeling expertise, the Company is able to create a new generation of multi-functional biological drug candidates that could potentially benefit patients globally. * For identification purpose only By Order of the Board Alphamab Oncology Xx. XX Xxxx Chairman and Executive Director Hong Kong, April 2, 2024
ABOUT THE COMPANY. The Company issues the contract described in this booklet and provides certain contract-related administrative services. We are a stock life insurance company organized under the insurance laws of the State of Connecticut in 1976 and an indirect wholly owned subsidiary of ING Groep N.V. (“ING”), a global financial institution active in the fields of insurance, banking and asset management. Securities are distributed through ING Financial Advisers, LLC and financial planning is offered by ING Financial Partners, Inc. (each members of the Financial Industry Regulatory Authority (“FINRA”) and the Securities Investor Protection Corporation (“SIPC”)) and other broker-dealers with which ING has selling agreements. ENROLLMENT Contributions will be sent to the Company by your employer and will be invested as directed by the plan sponsor until you, if allowed by the plan, request a different allocation of contributions or transfer the assets already in the ING HRA (see “THE ING HRA” below). The plan sponsor and the Company will supply you with complete enrollment information. THE ING HRA Your individual account balances are maintained for the plan participants by the TPA. The Company maintains one unallocated account for all employees/participants. THE ING HRA VARIABLE FUND INVESTMENT OPTIONS If allowed by your plan, the ING HRA offers a wide range of variable investment options through the contract. The variable investment options invest directly in shares of a corresponding mutual fund. Each underlying mutual fund has a different investment objective and more detailed information about their investment risks and fees and expenses can be found in the fund fact sheets you will receive, along with this booklet, at enrollment. At our discretion we may add, restrict or withdraw the availability of any such investment option. How the Variable Investment Options Work. These investment options fluctuate in value and involve investment risks. The value of the fund shares may increase or decrease, which will affect the value of the contract’s account. When contributions are allocated to a variable investment option, shares of the corresponding mutual fund are purchased by the Company and held in a pooled separate account. The separate account actually holds the fund shares. The contract’s account holds units of participation in the separate account. At the end of each day that the New York Stock Exchange (“NYSE”) is open (normally at 4:00 p.m. Eastern Time), a net asset va...
ABOUT THE COMPANY. Except as otherwise set forth on the Disclosure Schedule, Seller represents and warrants to Buyer that:
ABOUT THE COMPANY. CharterMac, through its subsidiaries, is one of the nation's leading full-service real estate finance companies, with a strong core focus on multifamily financing. CharterMac offers capital solutions to developers and owners of multifamily rental housing throughout the country and quality investment products to institutional and retail investors. For more information, please visit CharterMac's website at wxx.xxxxxxxxxx.xxx or contact the Corporate Communications Department directly at 800-000-0000. Certain statements in this press release may constitute forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and beliefs and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties are detailed in CharterMac’s Annual Report on Form 10-K for the period ended December 31, 2004, and in its other filings with the Securities and Exchange Commission. Such forward-looking statements speak only as of the date of this press release. CharterMac expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in CharterMac’s expectations with regard thereto or change in events, conditions, or circumstances on which any such statement is based. ### 47 AMERICAN MORTGAGE ACCEPTANCE COMPANY ANNOUNCES MANAGEMENT CHANGES New York, NY – November 8, 2005 – American Mortgage Acceptance Company (“AMAC” or the “Company”) (AMEX: AMC) today announced that Sxxxxx X. Xxxxxx will step down as Chairman, Chief Executive Officer and President of the Company, effective November 15, 2005. The Board of Trustees has appointed Jxxx X. Xxxx as interim Chairman and Chief Executive Officer and Mxxx X. Xxxxxxxxx as President. Mx. Xxxx is a member of the Board of Trustees of CharterMac, AMAC’s external advisor, as well as being the President of The Related Companies, LP (“TRCLP”). Mx. Xxxxxxxxx is the President of CharterMac and is also a member of CharterMac’s Board of Trustees. “After nearly twenty years of dedication to the CharterMac family of companies, including the last five years as Chief Executive Officer of both CharterMac and AMAC, Stuart has decided that at this juncture of his life, he would like to pursue othe...
ABOUT THE COMPANY. The Company is a leading biopharmaceutical company in China with a fully integrated proprietary biologics platform in bispecific and protein engineering. Differentiated in-house clinical pipeline of the Company includes the oncology drug candidates with one approved for marketing by the NMPA, three in late clinical stage and two in phase I clinical trial stage. The Company has developed various technologies and platforms of antibody-based therapies for oncology treatment and expertise in this regard. Benefitting from the proprietary protein engineering platforms and structure-guided molecular modeling expertise, the Company is able to create a new generation of multi-functional biological drug candidates that could potentially benefit patients globally.
ABOUT THE COMPANY. This summary highlights selected information contained in other parts of this prospectus. Because it is a summary, it does not contain all of the information that you should consider in making your investment decision. Before investing in our securities, you should read the entire prospectus carefully, including the information set forth under the heading “Risk Factors.” Company Overview Xxxx Global Holdings, Inc., a Delaware corporation formerly known as DPW Holdings, was incorporated in September 2017. We are a diversified holding company owning subsidiaries engaged in, among others, the following operating businesses: commercial and defense solutions, commercial lending, data center operations, cryptocurrency mining and advanced textile technology. Our direct and indirect wholly-owned subsidiaries include Xxxxxxx Worldwide, Inc. (“GWW”), TurnOnGreen, Corp., formerly known as Coolisys Technologies Corp. (“TOGI”), Digital Power Corporation, Xxxxxxx Power Electronics Ltd. (“Xxxxxxx Power”), Enertec Systems 2001 Ltd (“Enertec”), Relec Electronics Ltd. (“Relec”), Digital Power Lending, LLC (“DP Lending”), Xxxx Alliance, Inc. (“Xxxx Alliance”) and Tansocial LLC (“Tansocial”). We also have a controlling interest in Microphase Corporation (“Microphase”) and Xxxx Alliance has a controlling interest in Alliance Cloud Services, LLC (“ACS”) as well as Avalanche International Corp. (“Avalanche”). Xxxx Global Holdings was founded by Xxxxxx “Xxxx” Xxxx III, its Executive Chairman and is led by Xx. Xxxx, Xxxxxxx X. Xxxxx, its Chief Executive Officer and Vice Chairman and Xxxxx Xxxxxx, its President and General Counsel. Together, they constitute the Executive Committee, which manages the day-to-day operations of the holding company. The Company’s long-term objective is to maximize per share intrinsic value. All major investment and capital allocation decisions are made for the Company by Xx. Xxxx and the Executive Committee. The Company has three reportable segments: · GWW – defense solutions with operations conducted by Microphase, Enertec, Xxxxxxx Power and Relec, · TOGI – commercial electronics solutions with operations conducted by Digital Power Corporation and EV charging solutions, and · Xxxx Alliance – commercial lending through DP Lending, data center operations through ACS, textile treatment through Avalanche, digital marketing through Tansocial, digital learning and cryptocurrency mining operations. We operate as a holding company with operations conducted pri...
ABOUT THE COMPANY. We provide an interactive online service on the Internet to members and to health insurance providers (“HIPs”) and third party administrators (“TPAs”), consisting of information services, customer service, other services, content and communication capabilities facilitated through us, our affiliates, and/or service providers (collectively, the "Services"). The right to use the Brighter Platform is personal to you and is not transferable to any other person or entity. Except as we specifically state in this Agreement, you are responsible for protecting the confidentiality of your password(s) and other private information, if any. Everything we offer as Brighter is referred to in these Terms of Use collectively as the "Services". While some content on the Brighter Platform is viewable without your having submitted any information to us, to utilize any Services that require the Brighter Platform to know additional information about you, you must authorize the use and disclosure of your personal and health information for purposes of allowing us to provide the Services and as otherwise disclosed in our Privacy Policy.
ABOUT THE COMPANY. The Company is a leading clinical-stage biopharmaceutical company in China with a fully-integrated proprietary biologics platform in bispecific and protein engineering. Differentiated in-house pipeline of the Company consists of eight oncology drug candidates, including four in the phase I-III clinical trial development stage. The Company has developed various technologies and platforms of antibody-based therapies for oncology treatment and expertise in this regard. Benefitting from the proprietary protein engineering platforms and structure-guided molecular modeling expertise, the Company could potentially create a new generation of multi-functional bio-macromolecule new drug candidate that could potentially benefit patients globally. Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that it will be able to develop, or ultimately market, KN046 successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company. By Order of the Board Alphamab Oncology Xx. XX Xxxx Chairman and Executive Director Hong Kong, May 28, 2020
